Boehringer Ingelheim Agrees to Settle Pradaxa Litigation for $650 Million

Boehringer Ingelheim Agrees to Settle Pradaxa Litigation for $650 Million

By Burg Simpson
May 28, 2014
3 min read

Seth A. Katz and Burg Simpson Eldredge Hersh & Jardine, P.C. are pleased to announce that earlier today Boehringer Ingelheim Pharmaceuticals, Inc. and its related companies agreed to pay $650,000,000 to settle close to 4,000 claims brought on behalf of individuals who were injured after taking the company’s anticoagulant drug, Pradaxa (dabigatran etexilate).

Burg Simpson’s product liability lawyers have led the fight for injured victims since day one. On September 27, 2012, Burg Simpson shareholder Seth A. Katz was appointed by the Hon. David R. Herndon, United States District Court Chief Judge for the Southern District of Illinois, to serve as Co-Lead Counsel in the consolidated multidistrict litigation. Mr. Katz and the Burg Simpson team have been instrumental in negotiating settlements on behalf of claimants, including a substantial number of wrongful death claims.

Mr. Katz said, “While there are still milestones that have to be reached, this settlement will provide fair compensation to those participating individuals who were injured after taking Pradaxa. I am very pleased with the results achieved in this litigation. I am very proud to have been appointed to this important position by Judge Herndon and to be involved in the resolution reached in this litigation.”

Seth A. Katz is one of America’s leading trial lawyers, focusing his practice almost exclusively on pharmaceutical and medical device litigation. He is a past president of the National Trial Lawyers Mass Tort Trial Lawyers Association. In addition to being appointed as Co-Lead Counsel in the Pradaxa MDL, Mr. Katz has been appointed by federal judges to leadership positions in numerous high-profile litigations, including the DePuy Orthopaedics, Inc. ASR Hip Implant Products Liability Litigation (MDL 2197), and he has served in leadership roles in other litigations such as the Yaz/Yasmin (Drospirenone) Marketing, Sales Practices, and Products Liability Litigation (MDL 2100) and the Gadolinium-Based Contrast Agents Products Liability Litigation (MDL 1909).

Burg Simpson is a national leader in product liability and pharmaceutical litigations, having successfully litigated thousands of cases in state and federal courts over the last 30 years. The firm has obtained more the $1 Billion in successful verdicts, settlements, and judgments on behalf of its clients, and has secured more than 100 individual recoveries in excess of $1 Million.

With offices in Denver, Colorado, Cincinnati, Ohio, Phoenix, Arizona, Cody, Wyoming, and Steamboat Springs, Colorado, Burg Simpson Eldredge Hersh & Jardine, P.C. is a firm of award winning trial lawyers practicing in the areas of personal injury, mass torts, class actions, medical malpractice, product liability, insurance bad faith, employment law, workers’ compensation, commercial litigation, construction defects, and securities litigation.


View the official Press Release

Free case evaluation form